Two tests and one reference [General Sta­tis­tics]

posted by ElMaestro  – Denmark, 2020-08-31 12:23 (1474 d 08:56 ago) – Posting: # 21896
Views: 7,618

Hi Brus,

❝ If one test and two references of different regions are tested in a bioequivalence study, is it necessary a α adjustment?


❝ In my case, we want to demonstrate if the test product is bioequivalent to R1 (European product reference) or if test product is bioequivalent to R2 (Reference product in the United Kingdom).


❝ If I have not misunderstood, in this case, alpha should be penalized, even if they are from different regions and to market in different regions because of the word "OR"?


❝ Is there a way to not penalize alpha? If the "O" is changed to "AND"? Executing two different clinical trials (one for Europe and one for the UK)?


Here's a different way to look at it:
Can the same patient(s) be affected by your two tests? If yes, it is safer to use correction. If no, no correction should be necessary.

Pass or fail!
ElMaestro

Complete thread:

UA Flag
Activity
 Admin contact
23,224 posts in 4,878 threads, 1,654 registered users;
29 visitors (0 registered, 29 guests [including 6 identified bots]).
Forum time: 21:19 CEST (Europe/Vienna)

One of the symptoms of an approaching nervous breakdown
is the belief that one’s work is terribly important.    Bertrand Russell

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5